Beta-adrenoblockers in the treatment of hypertension in patients with diabetes mellitus: narrative synthesis of the literature
Keywords:
beta-adrenoblockers, diabetes mellitus, antihypertensive, diabetogenic effectAbstract
There is a high incidence of diabetes mellitus in people with hypertension, and the selection of antihypertensive therapy requires careful evaluation of efficacy and safety. Studies have demonstrated, that beta-adrenoblockers reduce total and cardiovascular morbidity and mortality in diabetic hypertensive patients. A narrative review of the literature was performed with the selection and analysis of scientific articles published in the Hinari database, academic literature, regarding the use of beta-adrenoblockers as antihypertensive therapy in diabetic patients. It was revealed, that beta-adrenoblockers possess distinctive pharmacokinetic and pharmacodynamic characteristics, depending on their action on adrenoreceptors and additional effects (nitric oxide release, antioxidant), as well as variable influence on glucidic and lipid metabolism. Thus, non-selective and beta-1-selective beta-adrenoblockers, without vasodilator action, induced weight gain, dysregulation of insulin sensitivity, altered lipid and carbohydrate profile, and a diabetogenic effect with risk of developing de novo diabetes. Beta-adrenoblockers with vasodilatory action (carvedilol, nebivolol) demonstrated neutral or improving effects on lipid profile (↑HDL, ↓LDL), insignificant influence on glycemic control, and antioxidant effect. Beta-adrenoblockers can be used for the treatment of hypertension, especially in patients with cardiovascular comorbidities (arrhythmias, heart failure, coronary artery disease). In patients with hypertension and diabetes mellitus it is recommended to use vasodilatory beta-adrenoblockers (carvedilol, nebivolol), without negative effects on lipid and glucose metabolism, and a low probability of de novo diabetes induction.
References
1. BARRESE, V., TAGLIALATELA, M. New advances in beta-blocker therapy in heart failure. In: Front Physiol. 2013, nr. 4:323.
https://doi.org/10.3389/fphys.2013.00323
2. BELL, D., GONCALVES, E. Diabetogenic effects of cardioprotective drugs. In: Diabetes Obes Metab. 2021, nr. 23(4), pp. 877-885.
https://doi.org/10.1111/dom.14295
3. CHEN, S., TIAN, P., ESTAU, D., LI, Z. Effects of beta-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. In: Frontiers in cell and developmental biology. 2023, nr. 11, pp. 1076107-1076107.
https://doi.org/10.3389/fcell.2023.1076107
4. CIŽMÁRIKOVÁ, R., HABALA, L., VALENTOVÁ, J., MARKULIAK, M. Survey of Pharmacological Activity and Pharmacokinetics of Selected beta-Adrenergic Blockers in Regard to Their Stereochemistry. In: Appl. Sci. 2019, 9(4), 625. https://doi.org/10.3390/app9040625
5. FERRI, C. The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines. In: Future Cardiol. 2021, nr. 17(8), pp. 1421-1433. https://doi.org/10.2217/fca-2021-0048
6. FRAGASSO, G., MARGONATO, A., SPOLADORE, R., LOPASCHUK, G.D. Metabolic effects of cardiovascular drugs. In: Trends in Cardiovascular Medicine. 2018, https://doi.org/10.1016/j.tcm.2018.08.001
7. GAMMONE, M.A., EFTHYMAKIS, K., D'ORAZIO, N. Effect of Third-Generation Beta Blockers on Weight Loss in a Population of Overweight-Obese Subjects in a Controlled Dietary Regimen. In: Journal of Nutrition and Metabolism. 2021, ID 5767306, 7 pages
https://doi.org/10.1155/2021/5767306
8. GHICAVÎI, V., BACINSCHI, N., GUŞUILĂ, Gh. Farmacologie. Chişinău. CEP Medicina. 2019. 996p. ISBN 978-9975-56-630-8
9. GUPTA, S., JHAWAT, D.V. Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene? In: Value in Health regional Issues. 2017, nr. 12 C, pp. 90-98. https://doi.org/10.1016/j.vhri.2016.10.005
10. Hipertensiunea arterială la adult. Protocol clinic național. (Vataman E., Curocichin Gh., Grosu A., Carauş A., Popescu L., Moiseeva A). Chişinău, 2020, 73p.
11. LASTRA, G., SYED, S., KURUKULASURIYA, L.R. et al. Type 2 diabetes mellitus and hypertension: an update. In: Endocrinol Metab Clin North Am. 2014, nr. 43(1), pp. 103-22. https://doi.org/10.1016/j.ecl.2013.09.005
12. LI, X.T. Beneficial effects of carvedilol modulating potassium channels on the control of glucose. In: Biomed Pharmacother. 2022 nr. 150:113057. https://doi.org/10.1016/j.biopha.2022.113057
13. MANCIA, G., KREUTZ, R., BRUNSTRÖM, M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). In: J Hypertens. 2023 Dec 1;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480
14. MANRIQUE, C., JOHNSON, M., SOWERS, M.J. Thiazide Diuretics Alone or With beta-Blockers Impair Glucose Metabolism in Hypertensive Patients With Abdominal Obesity. In: Hypertension. 2010, nr. 55, pp. 15-17. https://doi.org/10.1161/HYPERTENSIONAHA.109.142620
15. MARTI, H.P., PAVÍA LÓPEZ, A.A., SCHWARTZMANN, P. Safety and tolerability of beta-blockers: importance of cardioselectivity. In: Current Medical Research and Opinion. 2024, nr. 40(sup1), pp. 202455-62. https://doi.org/10.1080/03007995.2024.2317433
16. OLAWI, N., KRÜGER, M., GRIMM, D., INFANGER, M., WEHLAND, M. Nebivolol in the treatment of arterial hypertension. In: Basic Clin Pharmacol Toxicol. 2019, nr. 125(3), pp. 189-201. https://doi.org/10.1111/bcpt.13248
17. OZYILDIZ, A.G., EROGLU, S., BAL, U., ATAR, I., OKYAY, K., MUDERRISOGLU H. Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2017, nr. 22(1), pp. 65-70. https://doi.org/10.1177/1074248416644987
18. PRZEZAK, A., BIELKA, W., PAWLIK, A. Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities. In: Int.J.Mol.Sci. 2022, nr. 23, 6500. https://doi.org/10.3390/ijms23126500
19. SHAIKH, A.A. Practical Approach to Hypertension Management in Diabetes. In: Diabetes Ther. 2017, nr. 8(5), pp. 981-989.
https://doi.org/10.1007/s13300-017-0310-3
20. WHELTON, P.K., CAREY, R.M., ARONOW, W.S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. In: Hypertension. 2018 Jun;71(6):1269-1324.
https://doi.org/10.1161/HYP.0000000000000066
21. WILLIAMS, B., MANCIA, G., SPIERING, W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. In: Eur Heart J. 2018 Sep 1;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
22. WU, H.Y., HUANG, J.W., LIN, H.J. et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. In: BMJ. 2013, nr. 347, f6008. https://doi.org/10.1136/bmj.f6008
23. ZHANG, J., TONG, A., DAI, Y.et al. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta-analysis. In: J Clin Hypertens (Greenwich). 2019, nr. 21(8), pp. 1082-1090. https://doi.org/10.1111/jch.13598
24. ОПАРИН, А.А., БЛАГОВЕЩЕНСКАЯ, А.В., ОПАРИНА, Т.Н. Блокаторы beta-адренорецепторов: характеристика и особенности клинического применения. В: Схiдноєвропейський журнал внутрiшньої та сiмейної медицини. 2015, nr. 1, pp. 48-53.
https://doi.org/10.15407/internalmed2015.01.048
25. СЕМЕНКИН, А.А., НЕЧАЕВА, Г.И., ШУПИНА, М.И., ФИСУН, Н. И. Бета-адреноблокаторы в терапии артериальной гипертензии. В: Лечащий врач. 2015, nr. 7, pp. 12-14.
26. ЦЫРЛИН, В. А. Фармакология антигипертензивных средств. В: Регионарное кровообращение и микроциркуляция. 2020, nr. 19(2), pp. 75-88. https://doi.org/10.24884/1682-6655-2020-19-2-75-88
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
